Vivo Capital LLC boosted its stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 68.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,013,149 shares of the biotechnology company’s stock after buying an additional 413,149 shares during the period. Aurinia Pharmaceuticals accounts for 1.6% of Vivo Capital LLC’s portfolio, making the stock its 14th largest position. Vivo Capital LLC’s holdings in Aurinia Pharmaceuticals were worth $6,211,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. UBS Group AG boosted its stake in Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock valued at $824,000 after buying an additional 13,405 shares during the period. Jane Street Group LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $155,000. Cutler Capital Management LLC purchased a new stake in Aurinia Pharmaceuticals during the second quarter valued at approximately $184,000. Two Sigma Securities LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $240,000. Finally, TD Asset Management Inc. purchased a new stake in Aurinia Pharmaceuticals during the first quarter valued at approximately $241,000. 29.48% of the stock is owned by institutional investors.

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) opened at 6.05 on Friday. Aurinia Pharmaceuticals Inc has a 52 week low of $1.74 and a 52 week high of $10.54. The firm’s market capitalization is $503.80 million. The company’s 50 day moving average price is $6.34 and its 200-day moving average price is $6.16.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.10. The business had revenue of $0.33 million during the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 38.20% and a negative net margin of 16,648.93%. On average, equities research analysts expect that Aurinia Pharmaceuticals Inc will post ($0.74) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Vivo Capital LLC Increases Position in Aurinia Pharmaceuticals Inc (AUPH)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/08/13/vivo-capital-llc-increases-position-in-aurinia-pharmaceuticals-inc-auph.html.

Several research firms have recently commented on AUPH. Cantor Fitzgerald set a $14.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Friday. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. HC Wainwright lowered their target price on Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday, May 18th. Finally, Vetr cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price for the company. in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $9.28.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP).

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.